Cidara Therapeutics, Inc. (NASDAQ:CDTX)
Industry: Healthcare

Cidara Therapeutics, Inc., a biotechnology company, focuses on the discovery, development, and commercialization of novel anti-infectives for the treatment of diseases in the United States. Its lead product candidate is rezafungin acetate, a novel molecule in the echinocandin class of antifungals for the treatment and prevention of serious invasive fungal infections, including candidemia and invasive candidiasis, which are fungal infections associated with high mortality rates. The company, through its Cloudbreak platform, focuses on the treatment of infectious diseases that include viral and bacterial infections. The company was formerly known as K2 Therapeutics, Inc. and changed its name to Cidara Therapeutics, Inc. in June 2014. Cidara Therapeutics, Inc. was founded in 2012 and is headquartered in San Diego, California.

Current Quote*
Last: $1.879
Change: -0.021
Book: $1.592
Volume: 45,180

As Of: 10/22 13:00 ET
*Quotes delayed by 20min.

Graphs for CDTX

3 Month Graph

6 Month Graph

1 Year Graph